Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511534 | 0.83 | ALDH1A1 (0.40) | MEN1KMT2ACNR1CNR2MAPT | |
| SCHEMBL5860590 | 0.82 | KDM4E (0.39) | KMT2AMAPTALDH1A1KDM4ECYP2D6 | |
| SCHEMBL9146625 | 0.79 | MEN1 (0.33) | MEN1KMT2ACNR1CNR2HTT | |
| SCHEMBL5861779 | 0.78 | GAA (0.47) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL5861592 | 0.77 | AGTR2 (0.43) | ALDH1A1 | |
| SCHEMBL8372779 | 0.75 | SRC (0.42) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL7004971 | 0.75 | ELANE (0.38) | ALDH1A1ELANETDP1CYP2D6CYP1A2 | |
| SCHEMBL5860157 | 0.71 | GAA (0.37) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL9775971 | 0.70 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8741462 | 0.69 | PTGS2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050143318-A1 | Growth hormone secretagogues | DODGE JEFFREY A (US) | 2005-06-30 | — | — | US | disclosed |
| US-6828331-B1 | Non-peptidyl in nature and are, therefore, more metabolically stable than growth hormone, growth hormone releasing hormone, or analogs of either of these proteins | ELI LILLY AND COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1112071-A4 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1153034-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1112071-A1 | GROWTH HORMONE SECRETAGOGUES | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000049037-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000010565-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1999008697-A1 | TREATMENT OF CONGESTIVE HEART FAILURE WITH GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008699-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143318-A1 | Growth hormone secretagogues | GHSR, GHRHR, SSTR3 | MEN1 642/4885KMT2A 2280/4885CNR1 106/4885 |
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | MEN1 119/4885KMT2A 3972/4885CNR1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.